Oncotarget

Discover the significance of tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC) and its association with neoantigens and immune response. Learn about the shift to measuring TMB in mutations per megabase (>10 mut/Mb) and how high TMB levels can predict a positive response to immunotherapy in NSCLC patients. Explore the results of a cohort study on Stage 4 NSCLC patients, highlighting the impact of TMB on survival benefits and its correlation with smoking history and genetic alterations.

Researchers conducted a study on tumor mutational burden in non-small cell lung cancer, specifically looking at how TMB affects clinical outcomes in patients receiving immunotherapy. A high TMB may lead to a stronger immune response, making it a potential predictive biomarker for immuno-oncology treatment.

Dr. Lipkowitz and Dr. Endo Greer from NCI discuss how ONC201 kills breast cancer cells by targeting mitochondria, not dependent on TRAIL receptors or caspases. ONC201 induces cell membrane ballooning and rupture, AMP-dependent kinase phosphorylation, and ATP loss, enhancing cytotoxicity in the absence of glucose. The drug indirectly inhibits mitochondrial respiration, showing potential in cancer therapy.

Researchers explore genes responsible for endocrine therapy resistance in breast cancer, utilizing advanced statistical and computational methods. They identify 34 crucial genes related to resistance and triple negative breast cancer, highlighting the need for better understanding to improve treatments.

Guests from California State University discuss a research paper on secretomes from metastatic breast cancer cells. They delve into the effects on premetastatic tissues, the role of CD73-positive mesenchymal stem cells, and the impact of lipocalin II in creating a tumor-supportive environment in the lung.

The podcast explores the rise of endometrial cancer, the potential side effects of hysterectomies, and the research on the (pro)renin receptor in endometrial cancer biology. They discuss innovative therapeutic approaches, the role of PRR in cancer cell growth, viability, and its implications for diagnosis and treatment.

Researchers Mariana Perepitchka, Yekaterina Galat, and Dr. Vasiliy Galat discuss their 2020 research on Down syndrome iPSC model and tumor development. They explore the unique cancer profile of DS individuals, focusing on endothelial cells' role in preventing solid tumor growth. The podcast discusses molecular and phenotypic differences in DS endothelial cells, highlighting genes related to angiogenic pathways and potential new leukemia treatment targets.

Learn about Impact Journals' participation at the AACR Annual Meeting 2022, showcasing their dedication to cancer and aging research through journals like Oncotarget and Aging. Attendees are encouraged to connect with the Impact Journals team at booth No. 2012 and explore their website for more information.

Delve into the complexities of osteosarcoma, a rare bone cancer affecting both young and old patients. Learn how researchers are studying the IGF-1/mTOR and YAP/TAZ pathways to uncover potential treatment options. Discover the challenges of targeting mutations in osteosarcoma and the search for effective therapies.

Researchers are exploring virotherapy as a new method to treat multiple myeloma. Using oncolytic myxoma virus delivered through stem cell transplantation, they have seen promising results in eliminating MM cells in mouse models. The podcast discusses the efficacy of this adjunct virotherapy in targeting drug-resistant MM cells and improving survival rates.